November 10, 2011
1 min read
Save

Blacks with prostate cancer had poorer survival, less likely to undergo pelvic lymph node dissection than whites

Hayn MH. Cancer. 2011;doi:10.1002/cncr.26103.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Compared with white men, black men with well-differentiated prostate cancer and poorly differentiated tumors were less likely to undergo pelvic lymph node dissection and had poorer survival. Researchers found no racial disparity among men with moderately differentiated disease.

Researchers reviewed data collected in the SEER database on men diagnosed with prostate cancer and treated with radical prostatectomy or pelvic lymph node dissection (PLND) without radical prostatectomy from 2000 to 2002. The total cohort was 40,848 men; 76.7% white, 11% black, 8.4% Hispanic and 3.9% Asian. Median age at diagnosis was 61 years, and 77% of patients underwent PLND.

For men diagnosed with well-differentiated tumors, only 50% of Asians and 58.8% of blacks underwent PLND vs. 72.5% of whites. Among men who were diagnosed with moderately differentiated tumors, a significantly lower percentage of black (73.4%) and Hispanic men (73%) underwent the procedure compared with white men (75%). Similarly, a significantly lower percentage of black men with poorly differentiated tumors underwent PLND compared with white men (81.5% vs. 85.7%).

After controlling for age, marital status, tumor grade and SEER registry, researchers concluded that black men had lower odds (OR=0.91; 95% CI, 0.84-0.98) of undergoing PLND compared with whites. The odds for Hispanic and Asian men were about equal to that of white men. Men aged 50 to 59 years were also less like to receive PLND compared with men aged 60 to 69 years (OR=0.93; 95% CI, 0.88-0.98). Odds were similarly lower for men aged 70 to 79 years (OR=1.20; 95% CI, 1.11-1.30).

Twitter Follow HemOncToday.com on Twitter.